John Wallbillich

John Wallbillich

John Wallbillich

Position Title

Assistant Professor - Clinical
Gynecologic Oncology




Office Location

Karmanos Cancer Institute
Harper Professional Building
4100 John R., HP07GO
Detroit, MI 48201


Mailing Address

Karmanos Cancer Institute
4100 John R., HP07GO
Detroit, MI 48201


Office Phone


Office Fax


Education Training

(2009)Doctor of Medicine, University of Michigan Medical School, Ann Arbor, MI
(2004) B.S. in Biopsychology and Cognitive Science, with Distinction, University of Michigan College of Literature, Science, and the Arts Ann Arbor, MI

Postgraduate Training
(2016-2019)Women’s Reproductive Health Research Scholar, Women’s Reproductive Health Research Program (NIH K12) Medical College of Georgia, Augusta University, Augusta, GA
(2013-2016) Fellowship in Gynecologic Oncology, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH
(2009-2013)Residency in Obstetrics and Gynecology, Memorial Hermann Hospital Program, University of Texas Health Science Center at Houston, Houston, TX



Professional Experience

Faculty Appointments
(2019-Present) Assistant Professor - Clinical, Department of Oncology, Division of Gynecologic Oncology, Wayne State University, Detroit, MI
(2017-2019) Associate Faculty, Secondary Appointment, The Graduate School, Augusta University, Augusta, GA
(2016-Present) Adjunct Faculty, Secondary Appointment, Center for Biotechnology and Genomic Medicine, Medical College of Georgia, Augusta University, Augusta, GA
(2016-2019) Assistant Professor, Department of Obstetrics and Gynecology, Medical College of Georgia at Augusta University
Augusta, GA

Hospital and Other Professional Appointments
(2017-2019)Attending Gynecologic Oncologist, University Hospital, Augusta, GA
(2017-2019) Attending Gynecologic Oncologist, University Hospital Summerville (formerly Trinity Hospital) Augusta, GA
(2017-2019) Attending Gynecologic Oncologist, Doctors Hospital of Augusta, Augusta, GA
(2016-Present) Attending Gynecologic Oncologist, Augusta University Medical Center, Augusta, GA
(2004-2005) Research Assistant, Obstetric Anesthesiology
Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, MI


Major Professional Societies

(2018-Present) Member, Mid-Atlantic Gynecologic Oncology Society
(2013-Present) Member, Society of Gynecologic Oncology


Board Certification

American Board of Obstetrics and Gynecology 


Honors and Awards

(2019) GCC Superhero Award, Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA
(2012) Felix Rutledge Fellow, University of Texas MD Anderson Cancer Center, Department of Gynecologic Oncology, Houston, TX
(2004) James B. Angell Scholar, University of Michigan, Ann Arbor, MI
(2003) John and Josephine Castiglione Scholarship in Medical Ethics University of Michigan, Ann Arbor, MI
(2002) Biomedical Science Summer Research Fellowship, Undergraduate Research Opportunity Program, University of Michigan, Ann Arbor, MI




1. Dorayappan KDP, Wanner R, Wallbillich JJ, Saini U, Zingarelli R, Suarez AA, Cohn DE, Selvendiran K. Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3/Rab proteins. Oncogene 2018 Jul;37(28):3806-3821. [PMID: 29636548]

2. Saini U, Suarez AA, Naidu S, Wallbillich JJ, Bixel K, Wanner R, Bice J, Kladney RD, Lester J, Karlan BY, Goodfellow PJ, Cohn DE, Selvendiran K. STAT3/PIAS3 levels serve as "early signature" genes in the development of high-grade serous carcinoma from the fallopian tube. Cancer Research 2018 Apr;78(7):1739-1750. [PMID: 29339537]

3. Cohn DE, Backes FJ, Wallbillich JJ, Bixel K, Crafton SM, Neff R, ElNaggar AC, Smith B, Suarez AA. Recurrent low grade serous ovarian cancer in a 20 year old woman: A case from the Ohio State University College of Medicine. Gynecologic Oncology 2017 Mar;144(3)451-455. [PMID: 28161140]

4. Wallbillich JJ, Josyula S, Saini U, Zingarelli RA, Dorayappan KDP, Riley MK, Wanner RA, Cohn DE, Selvendiran K. High glucose-mediated STAT3 activation in endometrial cancer is inhibited by metformin: therapeutic implications for endometrial cancer. PLOS ONE 2017 Jan 23;12(1):e0170318. [PMID: 28114390]

5. Saini U, Naidu S, ElNaggar AC, Bid HK, Wallbillich JJ, Bixel K, Bolyard C, Suarez AA, Kaur B, Kuppusamy P, Hays J, Goodfellow PJ, Cohn DE, Selvendiran K. Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target. Oncogene 2017 Jan 12;36(2):168-181. [PMID: 27292260]

6. Wallbillich JJ, Forde B, Havrilesky LJ, Cohn DE. A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy. Gynecologic Oncology 2016 Jul;142(1):144-9. [PMID: 27106017]

7. Dorayappan KDP, Wallbillich JJ*, Cohn DC, Selvendiran K. The biological significance and clinical applications of exosomes in ovarian cancer. Gynecologic Oncology 2016 Jul;142(1):199-205. [PMID: 27058839] *co-first authorship

8. Costales AB, Milbourne AM, Rhodes HE, Munsell MF, Wallbillich JJ, Brown J, Frumovitz M, Ramondetta LM, Schmeler KM. Risk of residual disease and invasive carcinoma in women treated for adenocarcinoma in situ of the cervix. Gynecologic Oncology 2013 Jun;129(3):513-6. [PMID: 23541795]

9. Wallbillich JJ, Rhodes HE, Milbourne AM, Munsell MF, Frumovitz M, Brown J, Trimble CL, Schmeler KM. Vulvar Intraepithelial Neoplasia (VIN2/3): comparing clinical outcomes and evaluating risk factors for recurrence. Gynecologic Oncology 2012 Nov;127(2):312-5. [PMID: 22867736]

10. Wallbillich JJ, Nick AM, Ramirez PT, Watkins JL, Euscher ED, Schmeler KM. Vinblastine, cisplatin, cyclophosphamide, bleomycin, doxorubicin, and etoposide (VPCBAE) in the management of three patients with small-cell carcinoma of the ovary. Gynecologic Oncology Case Reports 2012 Feb 13;2(2)58-60. [PMID: 24371617]


Faculty Status


← Return to listing